Donor-transmitted malignancies in organ transplantation: assessment of clinical risk

Area of Science:

• Oncology
• Transplantation Medicine
• Public Health Policy

Background:

• The ongoing organ shortage necessitates exploring all potential donors, including those with malignant conditions.
• Current US practices lack a standardized risk assessment for tumor transmission from deceased donors, leading to organ wastage.
• The Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) established a Malignancy Subcommittee to address this gap.

Purpose of the Study:

• To develop a systematic framework for evaluating the risk of tumor transmission from deceased organ donors.
• To provide guidance on organ utilization from donors with a history of or active malignancy.
• To inform clinical decision-making in the United States regarding organ donation from potentially neoplastic donors.

Main Methods:

• Review of existing literature, including anecdotal reports on tumor transmission from organ donors.
• Consensus-based development of a six-level risk stratification system for donor malignancy.
• Categorization of specific tumors based on available data regarding transmission risk.
• Consideration of benign tumors and their malignant transformation potential.

Main Results:

• A six-tiered risk assessment framework for donor malignancy has been established.
• Specific guidance for organ utilization is provided for each risk category.
• The framework addresses various cancers, including renal cell carcinoma and central nervous system tumors.
• Emphasis is placed on balancing risk assessment with clinical judgment and emergent situations.

Conclusions:

• The developed framework provides a structured approach to managing organ donors with malignancy in the US.
• This resource aims to facilitate informed clinical decisions, potentially increasing organ utilization rates.
• The guidelines consider specific tumor types and the risk of malignant transformation.
• Individual clinical judgment remains paramount in organ procurement decisions.